Revenue Showdown: AstraZeneca PLC vs Takeda Pharmaceutical Company Limited

AstraZeneca vs Takeda: A Decade of Revenue Rivalry

__timestampAstraZeneca PLCTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014260950000001777824000000
Thursday, January 1, 2015247080000001807378000000
Friday, January 1, 2016230020000001732051000000
Sunday, January 1, 2017224650000001770531000000
Monday, January 1, 2018220900000002097224000000
Tuesday, January 1, 2019243840000003291188000000
Wednesday, January 1, 2020266170000003197812000000
Friday, January 1, 2021374170000003569006000000
Saturday, January 1, 2022443510000004027478000000
Sunday, January 1, 2023458110000004263762000000
Monday, January 1, 2024540730000004263762000000
Loading chart...

In pursuit of knowledge

Revenue Showdown: AstraZeneca vs Takeda

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Takeda Pharmaceutical Company Limited have been fierce competitors. Over the past decade, Takeda has consistently outpaced AstraZeneca in revenue, boasting figures that are nearly 100 times greater. From 2014 to 2023, Takeda's revenue surged by approximately 140%, reaching a peak in 2023. Meanwhile, AstraZeneca experienced a steady growth of around 75% during the same period. Notably, Takeda's revenue in 2023 was over 4 trillion, while AstraZeneca's was just under 46 billion. This stark contrast highlights Takeda's dominant market position. However, AstraZeneca's consistent growth trajectory suggests a promising future. The data for 2024 is incomplete, but the trends indicate that both companies are poised for continued success. As the pharmaceutical landscape shifts, these giants will undoubtedly play pivotal roles in shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025